VCN-01 combined with standard therapy significantly improved overall survival and progression-free survival in metastatic pancreatic ductal adenocarcinoma patients. The VIRAGE trial showed a 56% ...

Credit: J&J. The New Drug Application is supported by data from cohort 2 of the single-arm, phase 2b SunRISe-1 study. The device remains in the bladder and provides a sustained release of gemcitabine ...

Eraglusib combined with gemcitabine and nab-paclitaxel significantly improved overall survival in metastatic pancreatic ductal adenocarcinoma patients. The combination therapy showed a favorable ...

Sequential intravesical gemcitabine and docetaxel is associated with better oncologic outcomes compared with additional BCG in patients with BCG-unresponsive NMIBC and warrants a trial. Sequential ...

1 Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China 2 Department of Pathology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China ...

This study, known as ESPAC4, reported on with long-term follow-up of 732 patients in a phase 3, open-label, multicentre, randomised clinical trial of GemCap vs gemcitabine. Patients were seen in 92 ...

A dose-reduction strategy for a commonly used first-line combination in pancreatic cancer resulted in similar survival outcomes but improved tolerability, a randomized phase II study showed. In ...

Patients with locally advanced muscle-invasive bladder cancer may benefit from dose-dense gemcitabine and cisplatin. The treatment of preoperative dose-dense gemcitabine and cisplatin chemotherapies ...

Credit: Getty Images Investigators report their early clinical experience using intravesical sequential gemcitabine-docetaxel as first-line therapy for high-risk nonmuscle-invasive bladder cancer.

Urothelial carcinoma has long been treated with chemotherapy as the frontline standard of care, but recent trial results in the space have potential to add to the treatment armamentarium and improve ...